The changing face of severe childhood asthma: A comparison of two cohorts of children evaluated at National Jewish Health over the past 20 years

Allergy and Asthma Proceedings

Volumn 35, Issue 2, 2014, Pages 119-125

  Reddy, Monica B ^a   Doshi, Jayna ^a   Covar, Ronina ^a   Spahn, Joseph D ^a  

^a DEPARTMENT OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BECLOMETASONE HYDROFLUOROALKANE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; FLUNISOLIDE; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; GLUCOCORTICOID; HYDROCORTISONE; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING BETA AGONIST; METHACHOLINE; MOMETASONE FUROATE; OMALIZUMAB; PREDNISONE; SALBUTAMOL; TIOTROPIUM BROMIDE; TRIAMCINOLONE; UNCLASSIFIED DRUG; ANTIASTHMATIC AGENT;

ADOLESCENT; ADRENAL CORTEX DISEASE; ADULT; ARTICLE; ASTHMA; BODY HEIGHT; BODY WEIGHT; CATARACT; CHILD; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CUSHINGOID SYNDROME; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYALGIA; MYOPATHY; OSTEOPENIA; OSTEOPOROSIS; PRESCHOOL CHILD; RESPIRATORY TRACT INTUBATION; SCHOOL CHILD; SIDE EFFECT; TREATMENT DURATION; YOUNG ADULT; EPIDEMIOLOGY; LUNG FUNCTION TEST; MORBIDITY; ONSET AGE; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; UNITED STATES;

ADOLESCENT; AGE OF ONSET; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; COLORADO; CROSS-SECTIONAL STUDIES; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MORBIDITY; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84897051137     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2014.35.3727     Document Type: Article

References (39)

1. Torpy JM, Campbell A, and Glass RM. Chronic diseases of children. JAMA 303:682, 2010 (DOI:10.1001/jama.303.7.682.)
2. Vollmer WM, Markson LE, O'Connor E, et al. Association of asthma control with health care utilization: A prospective evaluation. Am J Respir Crit Care Med 165:195-199, 2002. (Pubitemid 34084457)
3. Chipps BE, Zeiger RS, Borish L, et al. TENOR Study Group. Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol 130:332-342.e10, 2012. (DOI: 10.1016/j.jaci. 2012.04.014. Epub ahead of print June 12, 2012.)
4. Weiss KB, Gergen PJ, and Hodgson TA. An economic evaluation of asthma in the United States. N Engl J Med 326:862-866, 1992.
5. Akinbami LJ, Moorman JE, Bailey C, et al. Trends in asthma prevalence, health care use, and mortality in the United States, 2001-2010. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. NCHS Data Brief, No. 94, May 2012.
6. Chan MT, Leung DY, Szefler SJ, and Spahn JD. Difficult-to-control asthma: Clinical characteristics of steroid-insensitive asthma. J. Allergy Clinical Immunology 101:594-601, 1998.
7. Harding SM. The human pharmacology of fluticasone propionate. Respir Med 84(suppl A):25-29, 1990. (Pubitemid 20376961)
8. Derendorf H, Hochhaus GS, Rohatagi S, et al. Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol 35:302-305, 1995.
9. Derendorf H, Hochhaus G, Meibohm B, et al. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol 101:S440-S446, 1998.
10. Lipworth BJ. New perspectives on inhaled drug delivery and systemic bioactivity. Thorax 50:105-110, 1995.
11. Barnes NC, Burke CM, Poulter LW, and Schleimer RP. The anti-inflammatory profile of inhaled corticosteroids: Biopsy studies in asthmatic patients. Respir Med 94(suppl F):S16-S21, 2000. (PMID:11059963.)
12. Nelson HS, Bernstein IL, Fink J, et al. Oral glucocorticosteroid-sparing effect of BUD administered by Turbuhaler: A double blind, placebo-controlled study in adults with moderate to severe chronic asthma. Chest 113:1264-1271, 1998. (Pubitemid 28223814)
13. Noonan M, Chervinsky P, Busse WW, et al. Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Am J Respir Crit Care Med 152:1467-1473, 1995.
14. Fish JE, Karpel JP, Craig TJ, et al. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. J Allergy Clin Immunol 106:852-860, 2000.
15. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med 170:836-844, 2004. (Pubitemid 39346477)
16. Pauwels RA, Löfdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 337:1405-1411, 1997.
17. O'Byrne P. Low dose inhaled budesonide and formoterol in mild persistent asthma: The OPTIMA randomized trial. Am J Respir Crit Care Med 164:1392-1397, 2001. (Pubitemid 33124016)
18. Lemanske RF, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma while receiving inhaled corticosteroids. N Engl J Med 362:975-985, 2010.
19. Matz J, Emmett A, Rickard K, et al. Addition of salmeterol to low-dose fluticasone: An analysis of asthma exacerbations. J Allergy Clin Immunol 107:783-789, 2001. (Pubitemid 32436910)
20. Korosec M, Novak RD, Myers E, et al. Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma. Am J Med 107:209-213, 1999. (Pubitemid 29421585)
21. Rosenthal RR, Busse WW, Kemp JP, et al. Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness. Chest 116:595-602, 1999. (Pubitemid 29428472)
22. Williams C, Crossland L, Finnerty J, et al. Case-control study of salmeterol and near-fatal attacks of asthma. Thorax 53:7-13, 1998. (Pubitemid 28178969)
23. Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 326:501-506, 1992.
24. Suissa S, Ernst P, Boivin J-F, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 149:604-610, 1994.
25. Castle W, Fuller R, Hall J, and Palmer J. Serevent nationwide surveillance study: Comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 306:1034-1037, 1993. (Pubitemid 23105961)
26. Nelson HS, Weiss ST, Bleecker ER, et al. The salmeterol multicenter asthma research trial. A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129:15-26, 2006. (Pubitemid 43265239)
27. Mann M, Chowdhury B, Sullivan E, et al. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 124:70-74, 2003. (Pubitemid 36851333)
28. Wolfe J, LaForce C, Friedman B, et al. Formoterol, 24 mcg bid and serious asthma exacerbations: Similar rates compared to formoterol 12 mcg bid, with and without extra doses taken on demand, and placebo. Chest 129:27-38, 2006. (Pubitemid 43265240)
29. Covar RA, Leung DYM, McCormick D, et al. Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. J Allergy Clin Immunol 106:651-659, 2000.
30. Reimer LG, Morris HG, and Ellis EF. Growth of asthmatic children during treatment with alternate-day steroids. J Allergy Clin Immunol 55:224-231, 1975.
31. Russell G. Asthma and growth. Arch Dis Child 69:695-698, 1993. (Pubitemid 24009919)
32. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 343:1054-1063, 2000.
33. Kelly HW, Sternberg AL, Lescher R, et al. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med 367:904-912, 2012.
34. Adinoff AD, and Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 309:265-268, 1983. (Pubitemid 13074917)
35. Rooklin AR, Lampert SI, Jaeger EA, et al. Posterior subcapsular cataracts in steroid-requiring asthmatic children. J Allergy Clin Immunol 63:383-386, 1979. (Pubitemid 10217676)
36. Dekhuijzen PN, and Decramer M. Steroid-induced myopathy and its significance to respiratory disease: A known disease rediscovered. Eur Respir J 5:997-1003, 1992.
37. Toogood JH. Complications of topical steroid therapy for asthma. Am Rev Respir Dis 141:S89-S96, 1990. (Pubitemid 20063276)
38. Boorsma M, Andersson N, Larsson P, and Ullman A. Assessment of the relative systemic potency of inhaled fluticasone and budesonide. Eur Respir J 9:1427-1432, 1996. (Pubitemid 26233785)
39. Clark DJ, Grove A, Cargill RI, et al. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 51:262-266, 1996. (Pubitemid 26086469)